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Abstract
Green tea catechins (GTCs) exert chemopreventive effects in many cancer models. Several studies
implicate the DNA synthesis marker minichromosome maintenance protein 7 (MCM7) in prostate
cancer progression, growth and invasion; representing a novel therapeutic target. In this study, we
investigated the effect of GTCs on MCM7 expression in the transgenic adenocarcinoma mouse
prostate model (TRAMP). DNA microarray, immunohistochemistry and western blot analysis
showed that GTCs significantly suppressed MCM7 in the TRAMP mice treated with GTCs. Our
study indicates that the cellular DNA replication factor MCM7 is involved in prostate cancer (CaP)
and MCM7 gene expression was reduced by GTCs. Together, these results suggest a possible role
of GTCs in CaP chemoprevention in which MCM7 plays a critical role.
Keywords
chemoprevention; green tea catechins; prostate cancer; transgenic adenocarcinoma mouse prostate
model; minichromosome maintenance protein 7
Introduction
Prostate cancer (CaP) is currently recognized as the most frequent form of cancer in American
men (Luo et al., 2002). According to the American Cancer Society, approximately 234 000
men will be diagnosed with CaP in the United States alone this year, and 27 350 men will die
of the disease (Jemal et al., 2006). The molecular events responsible for the progression of
prostate cancer from a relatively indolent disease to one that can be life threatening are unclear
(Luo et al., 2002). Since CaP is associated with a high morbidity and mortality rate (when the
disease is clinically significant) and a long latency phase of 20 to 40 years, it represents an
attractive target for chemoprevention (Siddiqui et al., 2006). A modest delay in the progression
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of this type of cancer chemoprevention could result in a substantial reduction in the incidence
of the disease and improve the quality of life (Saleem et al., 2003).
Green tea, a popular beverage consumed worldwide, has been known for some time to have
protective effects against some common types of cancer (Adhami et al., 2003; Doss et al.,
2005; Stuart et al., 2006; Kumar et al., 2007). Epidemiological studies have indicated that Asian
populations that consume tea on a regular basis have the lowest incidence of all types of cancer
including CaP as compared to their western counterparts (Jian et al., 2004; Sim and Cheng,
2005; Siddiqui et al., 2006). The chemopreventive effects of green tea appear to be mediated
by the polyphenolic compounds known as catechins. The main catechins found in green tea
are (-)-epicatechin (EC), (-)-epigallocatechin (EGC), (-)-epicatechin-3 gallate (ECG), and (-)-
epigallocatechin-3-gallate (EGCG). Among these, EGCG is the most abundant catechin that
has gained the most attention with respect to anticarcinogenic activity (Doss et al., 2005).
The TRAMP mouse model is a well-known autochthonous transgenic animal model of CaP
that was developed as a very important tool for understanding the earlier events in the
progression of this disease (Greenberg et al., 1995; Kaplan-Lefko et al., 2003). TRAMP mice
express SV40 early genes (T and t antigen, Tag) under the control of the prostate-specific rat
probasin promoter that leads to cell transformation within the prostate; mimicking the entire
spectrum of human CaP progression (Greenberg et al., 1995; Kaplan-Lefko et al., 2003). The
earliest pathology is prostatic intraepithelial neoplasia (PIN) as early as 12 weeks of age when
expression of the transgene is maximal. Over the next 6-week period TRAMP mice commonly
display progressive forms of adenocarcinoma and will ultimately develop poorly differentiated
carcinoma by the time they reach 24 to 30 weeks of age (Greenberg et al., 1995; Kaplan-Lefko
et al., 2003). Recent laboratory studies have indicated that green tea treatment can inhibit CaP
development in this model (Gupta et al., 2001; Caporali et al., 2004).
In this study, we used the TRAMP model to compare time-course changes of gene expression
in the prostate of wild-type (WT, non-transgenic), TRAMP water-fed and TRAMP mice treated
with GTCs. Using the Affymetrix Mouse Genome Gene Chip; minichomosome maintenance
protein 7 (MCM7) was identified as differentially overexpressed in TRAMP water-fed mice
at the 17 week time point compared to WT (non-transgenic) mice. MCM7expression levels
continued to notably increase in the TRAMP water-fed mice as CaP progressed into poorly
differentiated adenocarcinoma at 24 weeks of age. MCM7 is a key component of the DNA
helicase complex with a critical role in controlling DNA replication (Labib and Diffley,
2001; Stoeber et al., 2001; Lei, 2005). Recent studies have indicated that MCM7 is associated
with the aggressive phenotype of CaP; amplification and overexpression was notably linked
to relapse and metastasis (Padmanabhan et al., 2004; Honeycutt et al., 2006; Ren et al.,
2006). Since, MCM7 is believed to have an active role in CaP tumorigenesis; we investigated
the effect of GTCs on MCM7 expression in the TRAMP mice. We have shown for the first
time that GTCs suppresses a gene that is associated with prostate cancer progression, growth
and tumor invasion.
Results
Effect of green tea on tumor development
In order to evaluate a possible GTC chemopreventive effect, TRAMP and WT (non-transgenic)
mice 8 weeks of age were fed a solution of 0.3% GTC in tap water or tap water alone (controls)
as drinking fluid. At 24 weeks of age, about 80% of GTC treated mice did not developed
palpable tumor. However, 20% of TRAMP mice that were treated with GTCs did not respond
to treatment showed palpable and fully developed tumors at 24 weeks of age. All tumors were
confirmed by histology. Thus, GTC chemopreventive activity was evident in as many as 80%
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of the transgenic animals. These results fully confirm the data obtained previously by our group
(Caporali et al., 2004).
Time course changes in gene expression in the prostate of WT and TRAMP mice
Figure 1 shows a representative heat map of a small group of early differentiated genes that
were downregulated in the dorsolateral prostates of WT (non-transgenic) mice and upregulated
in the TRAMP water-fed mice at the 12 and 17 week time point. Several of these genes were
selected from the Affymetrix microarray analysis because they were upregulated (> 2.2 fold)
in the TRAMP water-fed mice compared to WT mice at 17 weeks of age. Among the list of
genes, further DNA microarray analysis indicated that MCM7 expression levels continued to
increase (> 11.8 fold) in the TRAMP water-fed mice at the 24 week time point compared to
the WT mice. MCM7 expression increased during tumor progression in the TRAMP water-
fed mice from the 12 to 24 week time point, and treatment with GTCs dramatically decreased
MCM7 expression starting at 12 weeks of age (Figure 1).
MCM7 protein expression is increased in prostate cancer and GTC treatment suppresses
MCM7 expression
Figure 2 shows immunohistochemical analysis of prostate tissue sections for MCM7 in WT
(non-transgenic), TRAMP water-fed, and TRAMP mice treated with GTCs. The dorsolateral
prostate of WT mice, composed of a single layer of epithelial cells and were rarely positive for
MCM7 staining (Figure 2A). A progressive increase in MCM7 protein expression was
observed in TRAMP water-fed mice during prostate cancer progression. High grade PIN was
observed in 12 week TRAMP mice; the cells exhibiting MCM7 staining were confined to the
basal layer of the prostate epithelium (Figure 2B). By the time TRAMP mice reach the age of
17 weeks, PIN lesions progress to well differentiated prostate cancer. In this stage, epithelial
cells invading through fibromuscular stromal layer were positive for MCM7 staining (Figure
2C). As shown in Figure 2D, the majority of cells in poorly differentiated CaP express MCM7
in TRAMP water-fed mice at 24 weeks of age. IHC indicated a marked reduction of MCM7
signal on GTC-fed TRAMP mice as compared to the TRAMP water-fed mice at 17 and 24
weeks (Figures 2C, D and E, F). In particular, in Figure 2F (arrow) only high-grade PIN lesions
were MCM7 positive, while normal monolayer cells within the same gland were negative to
MCM7 staining. Parallel analysis using the proliferation marker, Ki-67 was also performed on
contiguous sections of WT and TRAMP prostates at different stages of tumor development
(Figures 3A–F). Both, MCM7 and Ki-67 showed close similarity in the pattern of expression.
Figure 4 shows the percentage of positive MCM7 and Ki-67 cells in the prostates of WT and
TRAMP mice with or without GTC treatment at 12, 17, and 24 weeks. MCM7 was significantly
downregulated in the TRAMP treated with GTCs at 17 and 24 weeks compared to TRAMP
water-fed (P < 0.001). Western blot analysis further validated the loss of MCM7 expression
in the GTC-fed TRAMP mice (Figure 5A). The signal of MCM7 protein was only detectable
at 17 weeks and this protein accumulated at very high levels in the prostates of TRAMP mice
at 24 weeks (Figure 5A). The results from the densitometric analysis showed a significant (P
< 0.001) increase in MCM7 protein expression in the TRAMP water-fed mice at 24 weeks
compared to the TRAMP water-fed mice at 17 weeks (Figure 5B). In our experimental
conditions, MCM7 was undetectable at 12, 17, and 24 weeks in TRAMP mice receiving GTCs
(Figure 5A). Densitometric analysis revealed that GTC-fed TRAMP mice showed a significant
(P < 0.001) decrease in MCM7 protein expression as compared to age-matched TRAMP water-
fed mice (Figure 5B). Thus, it appears that MCM7 protein is upregulated during tumor growth
and the chemopreventive efficacy of GTCs in TRAMP mice decreased or delayed expression
levels of this protein.
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Discussion
Chemoprevention, by definition, is the means of cancer control in which the occurrence of the
disease can be entirely prevented, slowed or reversed by the administration of naturally
occurring or synthetic compounds (Brawley 2002; Klein and Thompson 2004; Siddiqui et al.,
2006). CaP is an ideal disease for chemoprevention studies because it is typically diagnosed
in men over the age of 50, and a slight delay in the onset and subsequent progression of the
disease could have valuable health benefits (Gupta et al., 2001; Siddiqui et al., 2006). The
TRAMP mouse model closely mimics clinical prostate cancer and is considered an ideal model
for studying CaP progression (Kaplan-Lefko et al., 2003). Laboratory studies have
demonstrated the utility of these mice for CaP chemoprevention and intervention studies
(Adhami et al., 2004; Caporali et al., 2004; Saleem et al., 2005).
Using DNA microarray analysis, a group of genes were identified in the TRAMP water-fed
mice whose expressions were upregulated relative to WT controls at 17 weeks of age (Figure
1). Among the list of genes, we found MCM7 to be uniquely overexpressed (11.8 fold greater)
during the later stages of CaP in the TRAMP water-fed mice as compared to WT control mice.
Further analysis of the microarray results suggested that GTC treatment notably inhibited
MCM7 expression in the TRAMP water-fed mice during CaP progression.
MCM7 is an essential component of the replication helicase complex (MCM2-7) (Lei, 2005).
In a process known as DNA replication licensing, the MCM complex prepares DNA replication
by binding to origins of DNA replication during the late M to early G1 phase of the cell cycle
(Lei, 2005). Increased expression of MCM proteins has been reported in a variety of
malignancies (Gonzalez et al., 2003; Duderidge et al., 2005; Schrader et al., 2005; Yang et al.,
2006), however, only MCM7 has been reported to be highly expressed in prostate cancer
(Padmanabhan et al., 2005). Recent prostate tumor studies, found MCM7 overexpression
strongly correlated with progression, invasion and relapse (Ren et al., 2005; Honeycutt et al.,
2006). In mice, MCM7 overexpression produced primary tumors 12 times larger than controls
and resulted in the rapid demise of mice bearing those tumors (Ren et al., 2005).
Our current findings agree with the previous reports. As CaP progressed in TRAMP water-fed
mice, MCM7 expression levels continued to increase and at 24 weeks of age, MCM7
expression levels were the highest compared to WT control mice. The majority of TRAMP
mice at 24 weeks of age will develop CaP that is invasive and capable of metastatic spread to
distant sites such pelvic lymph nodes and lungs (Kaplan-Lefko et al., 2003). The continuous
presence of MCM7 throughout the cell cycle not only recruits more cells into the proliferation
cycle but may also induce reinitation of improper DNA synthesis (Ren et al., 2005). Increased
proliferation of CaP cells ultimately results in tumor invasion and metastasis leading to
significant mortality in humans (Satariano et al., 2003).
One important consideration towards the intervention and prevention of CaP is the
development of endpoint surrogate biomarkers that can be correlated with staging of disease
along the course of tumor development (Saleem et al., 2005). MCM proteins are expressed at
high levels in proliferating cells but not in quiescent somatic cells, which allows for the
differentiation of malignant cancer cells from differentiated somatic cells, making these
proteins ideal diagnostic markers (Blow et al., 2002; Lei, 2005). Recently, Padmanabhan et
al., (2005) reported MCM7 to be a useful marker of proliferation in CaP, which in our laboratory
may be used for evaluating the efficacy of chemopreventive regimens such as GTCs. In our
results, MCM7 expression was notably suppressed in the TRAMP mice treated with GTC
compared to aged-matched TRAMP water-fed mice. At 24 weeks, our IHC data (Figures 2D–
F) indicated that TRAMP water-fed mice had poorly differentiated carcinoma in the prostate,
but in the TRAMP GTC-fed mice only PIN lesions were found. Therefore, TRAMP GTC-fed
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mice showed a marked delay in CaP tumor development. Western blot analysis, gave the same
experimental trend but with different sensitivity (Figure 5).
Reports have suggested that the MCM genes are E2F regulated (Ohtani et al., 1999). Over
expression of E2F has been shown to induce cellular DNA synthesis suggesting that genes
critically involved in regulation of DNA replication are targets of E2F (Degregori et al.,
1997; Ohtani et al., 1999; Muller et al., 2007), and E2F binding sites have been identified in
the human MCM7 promoter (Suzuki et al., 1998). GTCs may effect MCM7 expression because
green tea polyphenols have been found to downregulate the protein expression of E2F via
retinomblastoma (Rb) pathway (Ahmand et al., 2002). In most human tumors, the Rb pathway
is deregulated and when deregulated, Rb activates the E2F family of transcription factors, and
thereby inducing the expression of E2F-responsive genes such MCM7 (Ohtani et al., 1999;
Ishida et al., 2001; Degregori et al., 2004; Muller et al., 2007). Green tea treatment in TRAMP
mice could be targeting the Rb-E2F pathway, thereby suppressing E2F transcriptional
activation, consequently downregulating the expression of genes important for DNA
replication such as MCM7. Further studies are needed to address the molecular mechanism
and pathways of GTCs on MCM7.
In conclusion, our work and others have implicated MCM7 in prostate cancer progression,
growth and invasion. Our present findings indicate that GTC treatment could have a marked
effect in delaying the onset of CaP by suppressing the expression of MCM7. In addition, our
results support the use of MCM7 expression as a biomarker in testing the efficacy of GTC
treatment in CaP chemoprevention. Interactions of GTCs and MCM7 are currently being
pursued.
Experimental Procedures
Transgenic Animals and GTC Chemoprevention
All procedures involving laboratory animals conform to the Guide for the Care and the Use
of Laboratory Animals published by the US National Institute of Health (NIH publication No.
85-23, revised 1996). Tramp mice, heterozygous for the PB-Tag transgene, were maintained
in a C57BL/6 background. The PB transgene is generated using the minimal rat probasin (rPB)
regulatory sequence to target SV40 early gene (T and t; Tag) expression specifically to prostatic
epithelium (dorsolateral lobes of the prostate) (Kaplan-Lefko et al., 2003). Transgenic males
were routinely obtained as [TRAMPxC57BL/6]F1 offspring and characterized as described
previously (Kaplan-Lefko et al., 2003). GTCs were extracted from green tea leaves as
previously reported, content and purity were assessed by HPLC (EGC 5.5%; EC 12.2%; EGCG
51.9%; ECG 6.1%; total GTCs 75.7%, caffeine <1.0%) (Caporali et al., 2004). GTCs were
administered in the drinking water (Caporali et al., 2004) as freshly prepared 0.3% GTC
solution every Monday, Wednesday and Friday, starting at the age of 8 weeks. The
concentration of GTCs mimics an approximate consumption of 6 cups of green tea per day by
an average human (Gupta et al., 2001). Treatment is started at 8 weeks of age because the
transgene promoter is initially regulated by the androgens, before then, mice do not display
cancer lesions. The animals had access to laboratory chow ad libitum.
In this study, 3 different experimental groups of mice were considered: (i) wild-type (non-
transgenic) water-fed (controls); (ii) TRAMP water-fed (cancer is progressing); and (iii)
TRAMP treated with GTCs (cancer is delayed). For each experimental group, 9 animals were
sacrificed at 12, 17 and 24 weeks of age to study CaP progression in a time-course fashion.
Prostates were quickly removed from each animal; a small portion of the dorsolateral prostate
was used for pathological studies and the remaining tissue was homogenized and RNA was
extracted for microarray analysis. The dorsolateral prostate tissue used for pathological studies
was fixed in 10% zinc-buffered formalin overnight, transferred to 70% ethanol and then
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embedded in paraffin. Sections of 4 µm were cut, mounted on slides and stained with
hematoxylin and eosin for histological analysis. The stained slides were reviewed for the
presence of prostate cancer and classified according to previously described grading system
(Kaplan-Lefko et al., 2003).
RNA Extraction
Total RNA was extracted from murine prostates using RNAfast (Molecular Systems, San
Diego, CA) according to manufacturer's instructions and purified on Qiagen columns (Qiagen,
Valencia, CA). Three tissue pools were made from each experimental group by pooling 3
prostate glands together. Five µg aliquots from each RNA preparation were checked for RNA
quality by electrophoresis.
Microarray Analysis
The RNA was processed and hybridized to arrays using standard Affymetrix protocols (Dobbin
et al., 2005). The processed RNA was hybridized to GeneChip Mouse Genome 430 2.0 arrays
(Affymetrix, Santa Clara, CA). Three independent experimental samples were hybridized for
each of the 3 time points (12, 17, and 24 weeks) for each of the 3 experimental conditions WT
(non-transgenic), TRAMP water-fed, and TRAMP treated with GTCs. All of these arrays were
batch analyzed using the robust multi-array analysis (RMA) program in Bioconductor to
generate individual signal values for each probeset on each array. Significance analysis of
microarrays (SAM) was used to identify genes that appeared to be more highly expressed at
17 weeks than at 12 weeks in the TRAMP water-fed but not WT (non-transgenic) mice. This
list was further screened for genes that showed decreased expression at 17 and 24 weeks in
TRAMP mice treated with GTCs.
Immunohistochemical Analysis
For immunohistochemistry, 5 mice were used from each experimental group (WT (non-
transgenic), TRAMP water-fed, and TRAMP treated with GTCs) at each time point (12, 17,
and 24 weeks of age). Tissues were fixed in 10% zinc-buffered formalin overnight, transferred
to 70% ethanol and embedded in paraffin. 4 µm sections were cut and mounted on slides. Slides
were hydrated in xylene, graded alcohol and equilibrated in PBS. Antigen retrieval was
performed with sodium citrate (10 mM pH 6) using microwave for 10 minutes at 400W.
Endogenous peroxidase activity was quenched with 0.3% H2O2 in methanol. Non-specific
binding was blocked with rabbit normal serum (Pierce, Rockford, IL, USA). Immunostaining
was performed using monoclonal antibodies anti-MCM7 (Santa Cruz Biotechnology, Santa
Cruz, CA; dilution 1:50) and anti-Ki-67 clone MIB-1 (DakoCytomation S.p.A, Milan, Italy;
dilution 1:25). Slides were washed in PBS and incubated with biotinylated rabbit anti-mouse
IgG, F(ab)2 secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, dilution 1:200),
followed by peroxidase labeled streptavidin (Amersham Bioscience, Europe GmbH, Milan,
Italy). The antigen was visualized by 10-minute incubation with diaminobenzidine
tetrahydrochloride (DAB) (Sigma Chemical Co., St. Louis, MO). Negative controls were done
by excluding the primary monoclonal antibodies from the reaction. Counterstaining was
performed with hematoxylin (Sigma Chemical Co., St. Louis, MO) and cover slips were
mounted with Eukitt (O. Kindler GmbH & Co., Freiburg, Germany).
Assessment of Immunostaining
Each slide was evaluated and scored independently by one investigator in a blinded fashion.
Counts were performed on high power (x40 objective) from the most intensely stained areas.
Nuclear staining was considered representative of MCM7 and Ki-67; at least 500 nuclei were
counted. The mean values with standard deviations were used to compare the percentage of
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positive cells for MCM7 and Ki-67 in each experimental group (WT, TRAMP water-fed and
TRAMP treated with GTCs) at the 12, 17 and 24 week time point.
Western Blot Analysis
Lysates from frozen mouse prostates were homogenized in RIPA buffer (Tris HCl 50 mM, pH
7.4; NaCl 150 mM, Na-deoxycholate 0.25%, NP-40 1%, DNAse 50 µg/ml, RNAse 50 µg/ml),
added with Complete™ protease inhibitor according to manufacturer’s instruction (Roche
Diagnostics Corporation, Milan, Italy), and heated at 100 °C for 10 min in SDS-PAGE loading
buffer. The equivalent of 50 µg of total protein was loaded on each lane and resolved by
electrophoresis on 10% polyacrylamide gel and blotted onto a membrane. Immunoreactive
bands were detected with the Chemiluminescence Blotting Substrate (POD) (Roche
Diagnostics Corporation, Milan, Italy) using anti-MCM7 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and anti-Tubulin (Cell Signaling Technology, Danvers, MA, USA)
antibodies.
Densitometric Analysis
Films were scanned on BioRad Molecular Analyst and total volume per band was calculated
using BioRad Quantity One 4.2.3 software. Data are presented as mean ± SD followed by
statistical analysis.
Statistical Analysis
Differences in expression were tested for statistical significance between the experimental
groups using a two sample Student’s t test. P values less than 0.05 were considered statistically
significant.
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Figure 1.
Gene expression changes in the prostates of WT (non-transgenic), TRAMP water-fed and
TRAMP mice treated with GTCs. Gene expression values were normalized, log2-transformed,
and mean-centered to produce relative values. Each column represents pooled samples from 3
different prostate glands (dorsolateral) taken from WT, TRAMP water-fed and TRAMP treated
with GTCs at the 12, 17, and 24 week time point. Some genes have multiple Affymetrix probe
sets. Genes that are upregulated appear in red, and those that are downregulated appear in green.
A color bar (bottom) relates to the intensity of the differences in gene expression.
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Figure 2.
Immunohistochemical staining for MCM7 protein in the dorsolateral prostate of WT and
TRAMP mice. (A) WT (non transgenic) mouse at 24 weeks of age (20x); (B) TRAMP water-
fed mouse at 12 weeks of age (20x); (C) TRAMP water-fed mouse at 17 weeks of age (20x);
(D) poorly differentiated prostate cancer in TRAMP water-fed mouse at 24 weeks of age (20x);
(E) prostate section of a GTCs-fed TRAMP mouse at 17 weeks of age (20x); (F) prostate
section of a GTCs-fed TRAMP mouse at 24 weeks of age. MCM7 is not detectable in the
normal monolayer of epithelial cells of the gland (arrow) but specifically expressed in the
multilayer and high grade PIN lesions (40x).
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Figure 3.
Immunohistochemical staining for Ki-67 protein in the dorsolateral prostate of WT and
TRAMP mice. (A) WT (non transgenic) mouse at 24 weeks of age (20x); (B) TRAMP water-
fed mouse at 12 weeks of age (20x); (C) TRAMP water-fed mouse at 17 weeks of age (20x);
(D) poorly differentiated prostate cancer in TRAMP water-fed mouse at 24 weeks of age (20x);
(E) prostate section of a GTC-fed TRAMP mouse at 17 weeks of age (20x); (F) prostate section
of a GTC-fed TRAMP mouse at 24 weeks of age (20x).
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Figure 4.
Percentage of (A) MCM7 and (B) Ki-67 positive cells in the dorsolateral prostates of WT (non-
transgenic), TRAMP water-fed and TRAMP treated with GTCs at 12, 17 and 24 weeks. The
mean values with standard deviations were used to compare the percentage of positive cells
for MCM7 and Ki-67 in each experimental group at the 12, 17 and 24 week time point. Values
represent mean ± SD of five animals in each group. *, P < 0.05; ***, P < 0.001 compared with
aged-matched TRAMP water-fed mice.
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Figure 5.
Western blot analysis of MCM7 protein levels in the dorsolateral prostates of 12, 17 and 24
week-old WT (non-transgenic), TRAMP water-fed and TRAMP treated mice with GTCs.
Alpha-Tubulin antibody was used to show equal loading of the protein samples. Western blot
is a representative of one (pooled samples-3 mice per group) of three experiments performed.
(B) Histogram indicates the ratio between MCM7 and α-Tubulin obtained by densitometry
analysis of the immunoblot. Data are presented as mean ± SD of three animals in each group.
***, P < 0.001 compared to TRAMP treated with GTCs at 17 and 24 weeks of age.
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